Executive summary: ARMoR reports two years of progress advocating for policies that incentivize new antimicrobial development, with growing influence in the EU and beyond, a stronger consultancy arm, and plans to expand into antibiotic access in low- and middle-income countries (LMICs).
Key points:
ARMoR aims to reduce deaths from antimicrobial resistance (AMR) by promoting “pull incentive” policies that reward the development and global access of new antibiotics.
The group focuses on shaping EU legislation and national AMR plans, currently seeing over 50% odds that an EU antibiotic subscription model will be adopted.
ARMoR’s analysis has informed EU and G7 policy discussions and been cited by major stakeholders including IFPMA, EFPIA, and CARB-X.
Strategic shifts include using consultancy work for groups like the World Bank and Novo Nordisk Foundation to influence priorities and expand reach.
A new grant from the Founder’s Pledge Catalytic Impact Fund enables research on improving antibiotic access in LMICs.
The organization seeks $140,000 in new funding for 2026, with specified marginal funding options from $12,000 to $90,000 supporting policy research, operations, or EU advocacy.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, andcontact us if you have feedback.
Executive summary: ARMoR reports two years of progress advocating for policies that incentivize new antimicrobial development, with growing influence in the EU and beyond, a stronger consultancy arm, and plans to expand into antibiotic access in low- and middle-income countries (LMICs).
Key points:
ARMoR aims to reduce deaths from antimicrobial resistance (AMR) by promoting “pull incentive” policies that reward the development and global access of new antibiotics.
The group focuses on shaping EU legislation and national AMR plans, currently seeing over 50% odds that an EU antibiotic subscription model will be adopted.
ARMoR’s analysis has informed EU and G7 policy discussions and been cited by major stakeholders including IFPMA, EFPIA, and CARB-X.
Strategic shifts include using consultancy work for groups like the World Bank and Novo Nordisk Foundation to influence priorities and expand reach.
A new grant from the Founder’s Pledge Catalytic Impact Fund enables research on improving antibiotic access in LMICs.
The organization seeks $140,000 in new funding for 2026, with specified marginal funding options from $12,000 to $90,000 supporting policy research, operations, or EU advocacy.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, and contact us if you have feedback.